Month: July 2024

Follicular Lymphoma Pipeline 2024 | Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron, Pfizer

DelveInsight’s, “Follicular Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Follicular Lymphoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Follicular Lymphoma Pipeline Outlook

Key Takeaways from the Follicular Lymphoma Pipeline Report

  • July 2024:- Epizyme, Inc– A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma. Stage 1 is a safety run-in phase, was designed to evaluate the safety of the combination of tazemetostat and R2, as well as to establish the RP3D for Stage 2, which is now completed.
  • July 2024:- Novartis Pharmaceuticals– A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL). This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.
  • July 2024:- M.D. Anderson Cancer Center– Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma. To determine the efficacy of obinutuzumab in combination with CC-99282 as determined by complete response (CR) rate after six cycles of combination treatment for patients with previously untreated, high tumor burden follicular lymphoma (FL).
  • DelveInsight’s Follicular Lymphoma Pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Follicular Lymphoma treatment.
  • The leading Follicular Lymphoma Companies such as Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others.
  • Promising Follicular Lymphoma Therapies such as Golcadomide, Obinutuzumab, CC-99282, Epcoritamab, Prednisone, Odronextamab, and others.

Stay ahead with the most recent pipeline outlook for Follicular Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Follicular Lymphoma Approved Drugs

Follicular Lymphoma Emerging Drugs Profile

  • Mil62: Mab Works

MIL62 is a third-generation anti-CD20 antibody with a unique competitive position. MIL62 is the first domestically developed third-generation anti-CD20 antibody entering Phase III registration trial in China. MIL62 is self-developed by leveraging our ADCC-enhanced antibody platform. In in vitro and in vivo studies, MIL62 demonstrates stronger ADCC and anti-tumor activities than rituximab (first-generation anti-CD20 antibodies) and obinutuzumab (other third-generation anti-CD20 antibody). The company is implementing critical clinical development strategies to first pursue marketing approval from the NMPA for the treatment of relapsed and/or refractory FL patients and DLBCL patients. At the same time, MIL62 is being developed for previously untreated FL and DLBCL patients (a significantly larger patient population) by demonstrating clinical superiority over rituximab.

  • Loncastuximab tesirine: ADC Therapeutics

Loncastuximab tesirine-lpyl is an ADC composed of a humanized monoclonal antibody that binds to human CD19 and is conjugated through a linker to a PBD–dimer toxin. Once bound to a CD19-expressing cell, loncastuximab tesirine-lpyl is internalized into the cell, where enzymes release the PBD-based warhead. The warhead is designed to bind irreversibly to DNA to create highly potent interstrand cross-links that block DNA strand separation, thus disrupting essential DNA metabolic processes such as replication. This ultimately results in cell death. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Follicular Lymphoma.

  • NX-2127: Nurix

NX-2127 is an oral small molecule degrader of BTK and cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos). Cereblon immunomodulatory drugs that induce degradation IKZF1 and IKZF3 such as lenalidomide and pomalidomide are FDA approved for a variety of hematologic malignancies including multiple myeloma, follicular lymphoma, and mantle cell lymphoma. We hypothesize that the combination of BTK degradation and cereblon immunomodulatory activity will have enhanced therapeutic benefit in patients suffering from a variety of B-cell malignancies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Follicular Lymphoma.

  • ABBV-319: AbbVie

ABBV-319 is a novel oncology first-in-class steroid-based antibody-drug conjugate (ADC) targeting CD19 that is anticipated to have robust single-agent activity and provide significant clinical benefit as combination therapy in various B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). The mechanism of action involves the ADC binding to CD19 on the surface of B-cell cancer cells, followed by internalization into the cells through receptor-mediated endocytosis. Once inside, the linker component of the ADC is cleaved, releasing the cytotoxic drug payload, which then targets and kills the cancer cells. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Follicular Lymphoma.

Explore groundbreaking therapies and clinical trials in the Follicular Lymphoma Pipeline. Access DelveInsight’s detailed report now! @ Follicular Lymphoma Treatment Drugs

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Follicular Lymphoma Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Unveil the future of Follicular Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Follicular Lymphoma Market Drivers and Barriers

Scope of the Follicular Lymphoma Pipeline Report

  • Coverage- Global
  • Follicular Lymphoma Companies- Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, and others.
  • Follicular Lymphoma Therapies- Golcadomide, Obinutuzumab, CC-99282, Epcoritamab, Prednisone, Odronextamab, and others.
  • Follicular Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Follicular Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Follicular Lymphoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Follicular Lymphoma Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Follicular Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Follicular Lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Mil62: Mab Works
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Loncastuximab tesirine: ADC Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. NX-2127: Nurix
  15. Mid Stage Products (Phase II)
  16. Preclinical Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Follicular Lymphoma – Collaborations Assessment- Licensing / Partnering / Funding
  21. Follicular Lymphoma – Unmet Needs
  22. Follicular Lymphoma – Market Drivers and Barriers
  23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Follicular Lymphoma Pipeline 2024 | Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron, Pfizer

Peripheral T-Cell Lymphomas Pipeline 2024 | Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Dizal Pharmaceuticals

DelveInsight’s, “Peripheral T-Cell Lymphomas Pipeline Insight 2024” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Peripheral T-Cell Lymphomas pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peripheral T-Cell Lymphomas therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Peripheral T-Cell Lymphomas Pipeline. Dive into DelveInsight’s comprehensive report today! @ Peripheral T-Cell Lymphomas Pipeline Outlook

Key Takeaways from Peripheral T-Cell Lymphomas Pipeline Report

  • July 2024:- National Cancer Centre, Singapore– Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma. The goal of this clinical trial is to evaluate the efficacy and safety of Pembrolizumab in combination with Olaparib in participants with relapsed/refractory Peripheral T-cell Lymphoma (PTCL).
  • July 2024:- Chengdu Zenitar Biomedical Technology Co., Ltd– An Open-Label, Multicenter Phase IIa Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Puesta Mesylate for Injection for the Treatment of Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma.
  • DelveInsight’s Peripheral T-Cell Lymphomas Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Peripheral T-Cell Lymphomas treatment.
  • The leading Peripheral T-Cell Lymphomas Companies such as Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others.
  • Promising Peripheral T-Cell Lymphomas Therapies such as Etoposide, Prednisolone, Romidepsin, Ixazomib, Chidamide, and others.

Stay ahead with the most recent pipeline outlook for Peripheral T-Cell Lymphomas. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Peripheral T-Cell Lymphomas Treatment

Peripheral T-Cell Lymphomas Emerging Drugs Profile

  • HBI-8000: HUYA Bioscience International

The novel epigenetic drug, HBI-8000, is a member of the benzamide class of histone deacetylase inhibitors (HDACIs), working by controlling how tightly DNA is wound around histone proteins, which regulate gene expression. This alters the expression of several proteins involved in processes that arrest the growth of cancer cells, increase tumor immunity and change the tumor microenvironment. Evidence suggests that this mechanism increases the efficacy of other cancer agents such as checkpoint inhibitors.

Explore groundbreaking therapies and clinical trials in the Peripheral T-Cell Lymphomas Pipeline. Access DelveInsight’s detailed report now! @ New Peripheral T-Cell Lymphomas Drugs

Peripheral T-Cell Lymphomas (PTCL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Intra-tumoral
  • Molecule Type

Peripheral T-Cell Lymphomas Products have been categorized under various Molecule types such as

  • Monoclonal antibodies
  • Immunoglobulins
  • Small molecules
  • Pyrimidines
  • Proteins and Peptides
  • Product Type

Unveil the future of Peripheral T-Cell Lymphomas Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Peripheral T-Cell Lymphomas Market Drivers and Barriers

Scope of the Peripheral T-Cell Lymphomas Pipeline Report

  • Coverage- Global
  • Peripheral T-Cell Lymphomas Companies- Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others.
  • Peripheral T-Cell Lymphomas Therapies- Etoposide, Prednisolone, Romidepsin, Ixazomib, Chidamide, and others.
  • Peripheral T-Cell Lymphomas Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Peripheral T-Cell Lymphomas Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Peripheral T-Cell Lymphomas Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Peripheral T-Cell Lymphomas Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Peripheral T-Cell Lymphomas (PTCL): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Peripheral T-Cell Lymphomas (PTCL) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Peripheral T-Cell Lymphomas (PTCL) Collaboration Deals
  9. Mid Stage Products (Phase II)
  10. HBI-8000: HUYA Bioscience International
  11. F520: Shandong New Time Pharmaceutical Co., LTD
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. YY-20394: Shanghai YingLi Pharmaceutical Co. Ltd.
  15. Drug profiles in the detailed report…..
  16. Pre-clinical and Discovery Stage Products
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Peripheral T-Cell Lymphomas (PTCL) Key Companies
  20. Peripheral T-Cell Lymphomas (PTCL) Key Products
  21. Peripheral T-Cell Lymphomas (PTCL)- Unmet Needs
  22. Peripheral T-Cell Lymphomas (PTCL)- Market Drivers and Barriers
  23. Peripheral T-Cell Lymphomas (PTCL)- Future Perspectives and Conclusion
  24. Peripheral T-Cell Lymphomas (PTCL) Analyst Views
  25. Peripheral T-Cell Lymphomas (PTCL) Key Companies
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peripheral T-Cell Lymphomas Pipeline 2024 | Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Dizal Pharmaceuticals

Renal Cell Carcinoma Pipeline 2024 | AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GSK

DelveInsight’s, “Renal Cell Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Renal Cell Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Renal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Renal Cell Carcinoma Pipeline Report

  • July 2024:- Hospital das Clínicas de Ribeirão Preto- CLARA: Characterization of Somatic and Germline Mechanisms That Impact the Immunotherapy Treatment and Prognosis of Patients With Renal Cancer. The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).
  • July 2024;- Ipsen- A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors. The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
  • DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment.
  • The leading Renal Cell Carcinoma Companies such as AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
  • Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.

Stay ahead with the most recent pipeline outlook for Renal Cell Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Renal Cell Carcinoma Treatment

Renal Cell Carcinoma Emerging Drugs Profile

  • CM082: Betta Pharmaceuticals

CM082 series have the similar skeletal structures to Icotinib Hydrochloride, as the multi-target RTK (receptor tyrosine kinase) inhibitor, mainly targeting at VEGFR and PDGFR. The drug is being evaluated in phase III stage of development for the treatment of Renal Cell Carcinoma.

  • TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

TQB 2450 (formerly APL 502 and CBT 502) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1. Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the treatment of renal cell carcinoma.

  • IPI-549: Infinity Pharmaceuticals

IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The drug is being studied in phase II stage of development for the treatment of renal cell carcinoma.

  • CMN-001: ColImmune

Dendritic cells have been used by colimmune for the treatment of renal failure. CMN001 is a dendritic cell vaccine for renal cell carcinoma. The drug is being evaluated in phase II stage of development for the treatment of renal cell carcinoma.

Explore groundbreaking therapies and clinical trials in the Renal Cell Carcinoma Pipeline. Access DelveInsight’s detailed report now! @ New Renal Cell Carcinoma Drugs

Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type

Renal Cell Carcinoma Products have been categorized under various Molecule types such as

  • Bispecific Antibody
  • Peptides
  • Small molecule
  • Gene therapy
  • Product Type

Unveil the future of Renal Cell Carcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Renal Cell Carcinoma Market Drivers and Barriers

Scope of the Renal Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
  • Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
  • Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Renal Cell Carcinoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Renal Cell Carcinoma Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Renal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Renal Cell Carcinoma Collaboration Deals
  9. Late Stage Products (Phase III)
  10. TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. IPI-549: Infinity Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. AVB-S6-500: Aravive Inc.
  17. Drug profiles in the detailed report…..
  18. Preclinical Stage Products
  19. Drug Name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Renal Cell Carcinoma Key Companies
  23. Renal Cell Carcinoma Key Products
  24. Renal Cell Carcinoma – Unmet Needs
  25. Renal Cell Carcinoma – Market Drivers and Barriers
  26. Renal Cell Carcinoma – Future Perspectives and Conclusion
  27. Renal Cell Carcinoma Analyst Views
  28. Renal Cell Carcinoma Key Companies
  29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Renal Cell Carcinoma Pipeline 2024 | AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GSK

Metastatic Renal Cell Carcinoma Pipeline 2024 | AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics

DelveInsight’s, “Metastatic Renal Cell Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Metastatic Renal Cell Carcinoma pipeline landscape. It covers the Metastatic Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Metastatic Renal Cell Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Metastatic Renal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report

  • July 2024:- Ipsen- A Phase II, Multicentre, Open-label Study of Cabozantinib as 2nd Line Treatment in Subjects With Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors.
  • July 2024:- Hospital das Clínicas de Ribeirão Preto- The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).
  • DelveInsight’s Metastatic Renal Cell Carcinoma Pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Metastatic Renal Cell Carcinoma treatment.
  • The leading Metastatic Renal Cell Carcinoma Companies such as AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd and others.
  • Promising Metastatic Renal Cell Carcinoma Therapies such as Cabozantinib, Pembrolizumab, Epacadostat, Sunitinib, BGB-A445, Tislelizumab, and others.

Stay ahead with the most recent pipeline outlook for Metastatic Renal Cell Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Renal Cell Carcinoma Treatment

Metastatic Renal Cell Carcinoma Emerging Drugs Profile

  • Olaparib: AstraZeneca

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014. Currently, it is in Phase II stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.

  • Atezolizumab: Genentech

Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. Currently, it is in Phase III stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.

  • TP-1454: Sumitomo Dainippon Pharma

TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator,that is currently being evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors (NCT04328740). TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.

Explore groundbreaking therapies and clinical trials in the Metastatic Renal Cell Carcinoma Pipeline. Access DelveInsight’s detailed report now! @ New Metastatic Renal Cell Carcinoma Drugs

Metastatic Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

Metastatic Renal Cell Carcinoma Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

Unveil the future of Metastatic Renal Cell Carcinoma treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Metastatic Renal Cell Carcinoma Market Drivers and Barriers

Scope of the Metastatic Renal Cell Carcinoma Pipeline Report

  • Coverage- Global
  • Metastatic Renal Cell Carcinoma Companies- AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd and others.
  • Metastatic Renal Cell Carcinoma Therapies- Cabozantinib, Pembrolizumab, Epacadostat, Sunitinib, BGB-A445, Tislelizumab, and others.
  • Metastatic Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Metastatic Renal Cell Carcinoma therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Metastatic Renal Cell Carcinoma Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Renal Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Atezolizumab: Genentech
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Olaparib: AstraZeneca
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. TP-1454: Sumitomo Dainippon Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Renal Cell Carcinoma Key Companies
  21. Metastatic Renal Cell Carcinoma Key Products
  22. Metastatic Renal Cell Carcinoma- Unmet Needs
  23. Metastatic Renal Cell Carcinoma- Market Drivers and Barriers
  24. Metastatic Renal Cell Carcinoma- Future Perspectives and Conclusion
  25. Metastatic Renal Cell Carcinoma Analyst Views
  26. Metastatic Renal Cell Carcinoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Renal Cell Carcinoma Pipeline 2024 | AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics

Metastatic Hepatocellular Carcinoma Pipeline 2024 | CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics Inc., Eureka Therapeutics Inc., Krystal Biotech Inc.

DelveInsight’s, “Metastatic Hepatocellular Carcinoma Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic Hepatocellular Carcinoma pipeline landscape. It covers the Metastatic Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Metastatic Hepatocellular Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Metastatic Hepatocellular Carcinoma Pipeline Outlook

Key Takeaways from the Metastatic Hepatocellular Carcinoma Pipeline Report

  • July 2024:- Hoffmann-La Roche– A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma.
  • July 2024:- Asan Medical Center- Multicenter Phase 2 Trial of Lenvatinib in Patients With Unresectable or Metastatic Hepatocellular Carcinoma After Progression on First-line Atezolizumab Plus Bevacizumab.
  • July 2024:- AbbVie– A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment.
  • DelveInsight’s Metastatic Hepatocellular Carcinoma Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic Hepatocellular Carcinoma treatment.
  • The leading Metastatic Hepatocellular Carcinoma Companies such as CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc, Shanghai Henlius Biotech, and others.
  • Promising Metastatic Hepatocellular Carcinoma Therapies such as Atezolizumab, Bevacizumab, Tiragolumab, HLX53 (1000mg), Lenvatinib, and others.

Stay ahead with the most recent pipeline outlook for Metastatic Hepatocellular Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Hepatocellular Carcinoma Treatment

Metastatic Hepatocellular Carcinoma Emerging Drugs Profile

  • CS1003: CStone Pharmaceuticals

CS1003 or Nofazinlimab is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed in solid tumors. Nofazinlimab shows comparable high binding affinities to the PD-1 of humans, cynomolgus monkey, and mouse, and can block the interaction of PD-1 with its ligands PD-L1 and PD-L2. The U.S. FDA has granted nofazinlimab Orphan Drug Designation (ODD) in July 2020 for the treatment of patients with HCC. CStone formed a strategic collaboration agreement with EQRx, under which EQRx licensed the exclusive rights to two immuno-oncology assets, sugemalimab and nofazinlimab, for development and commercialization outside of Greater China. CStone retains rights to nofazinlimab in Greater China, where it can continue to pursue development as a monotherapy or as part of its combination strategy for this drug. Currently, the drug is in Phase III stage of its development for the treatment of hepatocellular carcinoma.

  • Casdozokitug: Coherus BioSciences

Casdozokitug is a human anti-IL-27 antibody designed to inhibit the activity of this immune regulatory cytokine. The company is focused on developing casdozokitug in particular tumor types where IL-27 secreted from macrophages appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with immune checkpoint inhibitors. Preclinical studies have shown that treatment with casdozokitug blocks the immunosuppressive biologic effects of IL-27, resulting in immune cell activation in combination with other cancer therapies including anti-PD-1 therapy, as well as anti-tumor effects. Casdozokitug has been granted Orphan Drug designation and Fast Track designation for the treatment of refractory hepatocellular carcinoma from the FDA. It is the first IL-27 antibody to enter the clinic. Currently, the drug is in Phase II stage of its development for the treatment of hepatocellular carcinoma.

  • TTI-101: Tvardi Therapeutics

TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in inhibiting STAT3 activation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. In its first-in-man Phase 1 trial conducted in patients with relapsed/refractory tumors, TTI-101 monotherapy was well-tolerated and had clinical activity across a broad range of tumors including multiple durable radiographic objective responses. Currently, the drug is in Phase II stage of its development for the treatment of hepatocellular carcinoma.

  • ST316: Sapience Therapeutics, Inc.

ST316, a first-in-class antagonist of the interaction between ß-catenin and its co-activator BCL9, is being evaluated in the Phase I portion of a Phase I-II clinical study in patients with selected advanced unresectable and metastatic solid tumors. ST316-101 is an open-label, two-part study. The Phase I dose-escalation portion of the study is designed to determine the safety, tolerability, PK, and PD of ST316 in patients with selected advanced solid tumors likely to harbor abnormalities of the Wnt/ß-catenin signaling pathway. The Phase II dose-expansion portion aims to continue to assess the safety of ST316 as well as proof of concept in four specific tumor types known to harbor abnormalities of the Wnt/ß-catenin signaling pathway. Currently, the drug is in Phase I/II stage of its development for the treatment of hepatocellular carcinoma.

Explore groundbreaking therapies and clinical trials in the Metastatic Hepatocellular Carcinoma Pipeline. Access DelveInsight’s detailed report now! @ New Metastatic Hepatocellular Carcinoma Drugs

Metastatic Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Metastatic Hepatocellular Carcinoma Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Unveil the future of Metastatic Hepatocellular Carcinoma treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Metastatic Hepatocellular Carcinoma Market Drivers and Barriers

Scope of the Metastatic Hepatocellular Carcinoma Pipeline Report

  • Coverage- Global
  • Metastatic Hepatocellular Carcinoma Companies- CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc, Shanghai Henlius Biotech, and others.
  • Metastatic Hepatocellular Carcinoma Therapies- Atezolizumab, Bevacizumab, Tiragolumab, HLX53 (1000mg), Lenvatinib, and others.
  • Metastatic Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Metastatic Hepatocellular Carcinoma therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Metastatic Hepatocellular Carcinoma Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Hepatocellular Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. CS1003: CStone Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Casdozokitug: Coherus BioSciences
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ST316: Sapience Therapeutics, Inc.
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Hepatocellular Carcinoma Key Companies
  21. Metastatic Hepatocellular Carcinoma Key Products
  22. Metastatic Hepatocellular Carcinoma- Unmet Needs
  23. Metastatic Hepatocellular Carcinoma- Market Drivers and Barriers
  24. Metastatic Hepatocellular Carcinoma- Future Perspectives and Conclusion
  25. Metastatic Hepatocellular Carcinoma Analyst Views
  26. Metastatic Hepatocellular Carcinoma Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Hepatocellular Carcinoma Pipeline 2024 | CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics Inc., Eureka Therapeutics Inc., Krystal Biotech Inc.

Cloud OSS BSS Market Trends, Opportunities, Future Growth, Business Scenario, Share, Size, Scope, Key Segments and Forecast to 2027

“Amdocs (US), Ericsson (Sweden), Huawei (China), Netcracker (US), Oracle (US), HPE (US), Optiva (Canada), Nokia (Finland), CSG (US), ZTE (China), Comarch (Finland), Subex (India), STL (India), TEOCO (US), IBM (US), InfoVista (US), Comviva (India), Cerillion (UK).”
Cloud OSS BSS Market by Component ((Solutions and Services), Solution (OSS and BSS), Service (Professional and Managed Services)), Cloud Type (Public, Private, and Hybrid), Operator Type, Organization Size and Region – Global Forecast to 2027.

MarketsandMarkets forecasts the Cloud OSS BSS Market size to grow from USD 20.1 billion in 2022 to USD 36.6 billion by 2027, at a Compound Annual Growth Rate (CAGR) of 12.8% during the forecast period. The presence of various key players in the ecosystem has led to competitive and diverse market. The demand for improving network infrastructure to support various technologies is driving the growth cloud OSS BSS solutions. Increasing technological and 5G adoption is paving the way for cloud OSS BSS market.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=31137795  

By component, the services segment to have a higher growth during the forecast period

The cloud OSS BSS services segment is expected to have a higher growth rate during the forecast period. The cloud OSS BSS market, by service, is segmented into professional services and managed services. The need for consulting expertise to guide the enterprises to deploy the right solutions to improve operational efficiency will drive the demand for professional services. Managed services, focused on critical business issues, current requirements, and future growth opportunities, are majorly implemented by the telecom industry to enhance their service and business efficiency. This is expected to propel the demand for best-in-class services in this market.

By BSS solution, the billing and revenue management segment to account for the highest market share during the forecast period

In BSS solution, the billing and revenue management segment is expected to have the highest market share during the forecast period. Billing and revenue management solutions are designed to handle the accounting challenges of telecom companies with complex revenue streams and billing requirements. The main drivers for the growth of billing and revenue management solutions includes, the need to assist telecom operators in handling all bill-related processes across various lines of business and fulfill the need for highly efficient ecosystems and deliver a range of capabilities. Also, the need for CSPs to offer digitalized services to attract new customers and increase customer retention will drive the demand for billing and revenue management solutions in the market.

North America region to account for highest market share in cloud OSS BSS market

North America is one of the prominent regions in the cloud OSS/BSS market. Some top companies, such as Oracle, IBM, Amdocs, and HPE, are headquartered in the region. North America can further be considered one of the leading regions in the adoption of 5G and IoT technologies. CSPs in the region are enhancing their networking infrastructure to meet the increasing demand for 5G services in the future. Cloud OSS BSS is expected to play a key role in the development of new networking infrastructure. The deployment of a 5G network in the region is expected to boost the demand for cloud OSS/BSS solutions in the region. The key drivers such as increased focus on the rapid adoption of 5G and other technologies by vendors in North America would drive the growth of the cloud OSS BSS market. Also, tough competition among telecom players in the US to provide quality services has also contributed to the demand for cloud OSS BSS solutions and services in the region.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=31137795  

Unique Features in the Cloud OSS BSS Market

Scalability is one of the best things about Cloud OSS/BSS solutions. These solutions make it simple for organizations to adapt their operations dynamically by scaling up or down in response to demand. For telecom operators who have to swiftly launch new services and deal with varying workloads, this flexibility is essential.

Solutions for cloud-based OSS/BSS dramatically lower operating and capital expenses (OPEX and CAPEX, respectively). Businesses can avoid the high maintenance expenses of on-premises gear and software by utilizing cloud infrastructure. Better resource allocation and financial management are made possible by this pay-as-you-go strategy.

Platforms for cloud OSS/BSS allow for the quick deployment of new features and services. For telecom operators to remain competitive, they must be nimble enough to react swiftly to changes in the market and in technology.

The goal of contemporary Cloud OSS/BSS solutions is to improve client satisfaction. They give suppliers with AI-driven insights and sophisticated analytics to better understand consumer behavior and preferences. Improved client interaction, proactive problem solving, and individualized service offers are all made possible by this insight.

Platforms for cloud OSS/BSS are designed to easily interface with a wide range of other technologies and systems, such as network management systems, CRM, and ERP. Through the elimination of silos and enhancement of general business procedures, interoperability guarantees a unified and effective operating environment.

Major Highlights of the Cloud OSS BSS Market

The telecom industry’s requirement for scalable, adaptable, and affordable solutions is fueling the market expansion for Cloud OSS (Operations Support Systems) and BSS (Business Support Systems). Robust cloud-based OSS/BSS solutions are becoming more and more necessary to manage operations and business processes effectively as telecommunications companies grow their offerings and clientele.

One of the main advantages of the Cloud OSS/BSS market is that these solutions are naturally flexible and scalable. Cloud-based OSS/BSS platforms, in contrast to traditional on-premises systems, are easily scaleable up or down based on demand, allowing telecom operators to quickly respond to shifting market conditions and customer requirements without having to pay hefty infrastructure expenses.

Because cloud OSS/BSS solutions eliminate the need for considerable upfront hardware and software investments, they result in significant cost reductions. Telecom operators can optimize their operational expenditure by paying for just the resources they utilize thanks to cloud services’ pay-as-you-go approach.

Telecom operators need the agility that cloud-based OSS/BSS solutions offer if they want to remain competitive. These platforms facilitate the quick rollout of new products and services, cutting down on time-to-market and enabling providers to react swiftly to changing consumer expectations and technology breakthroughs.

Telecom operators place a high priority on improving the customer experience, and cloud OSS/BSS solutions are essential to reaching this objective. These platforms enable suppliers to comprehend client behavior and preferences, enabling individualized service offers, by providing advanced analytics and AI-driven insights.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=31137795  

Top Companies in the Cloud OSS BSS Market

Few globally established players such as Amdocs (US), Ericsson (Sweden), Netcracker (US), Huawei (China), HPE (US), and Oracle (US) are dominating the cloud OSS BSS market. In this market various strategies such as enhancements; partnerships, expansions, new product launches, collaboration, agreements, and acquisitions; and other growth strategies adopted by the top key players.

Amdocs launched a 5G native CES 21, which is the latest version of its cloud-based OSS-BSS integrated suite. It enables service providers to build, deliver, and monetize advanced services, leveraging their investments in technologies, such as 5G standalone network, Multi-access Edge Computing (MEC), SDN, AI and ML, and the cloud. Samsung and Amdocs collaborated to accelerate the delivery of 5G and 4G network solution. Amdocs entered into an agreement with Hungary’s Magyar Telekom to modernize and digitalized its business support system. The company has acquired Sourced Group to strengthen its capability and bring the communication industry to cloud. Amdocs and Google Cloud announced a strategic partnership to deliver Amdocs’ leading OSS and BSS systems on Google Cloud and create solutions and services to help communications companies modernize, automate, and digitize with the cloud.

Ericsson is a distinguished global player, providing multinational networking and telecommunications equipment. It operates through four business segments: networks, digital services, managed services, emerging businesses, and others. Together with Telefónica, and Samsung, developed a solution for 5G interactive calling, based on IMS data channel standard and  vEricsson Cloud IMS network. Ericsson has entered into partnership with MTS and Ericsson entered into a partnership to expand 5G-ready networks in Russia. The key focus of the company is to support Industry 4.0. the company has also partnered with AWS to move Ericsson’s BSS digital portfolio to public cloud. It will modernize the services and improve the customer experience.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/cloud-oss-bss-market-31137795.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cloud OSS BSS Market Trends, Opportunities, Future Growth, Business Scenario, Share, Size, Scope, Key Segments and Forecast to 2027

Fuel Cell Market Forecast to Grow at 27.1% CAGR from 2024 to 2031 | SkyQuest Technology

“Skyquest Technology”
Fuel Cell Market Size, Share, Growth Analysis, By Size(Small-Scale, Large Scale), By Fuel Type(Hydrogen, Methanol, Ammonia, Other Fuel Type), By Type(Proton Exchange Membrane Fuel Cell, Solid Oxide Fuel Cell, Phosphoric Acid Fuel Cell, Alkaline Fuel Cell), By Components(Stack (Cells, Interconnects, End Plates, Sea Plants), By Application(Portable, Stationary (Primary, Backup, Combined Heat & Power)), By Region – Industry Forecast 2024-2031

Fuel Cell Market size was valued at USD 2.90 Billion in 2022 and is poised to grow from USD 3.69 Billion in 2023 to USD 25.10 Billion by 2031, at a CAGR of 27.1% during the forecast period (2024-2031).

By interacting with an oxidizer, electrochemical fuel cells generate electricity. Electrolytes transport charged particles between positive and negative electrodes. There are different types of fuel cells, but they all work the same way. There are also other fuel sources like methanol and natural gas, but fuel cells use hydrogen ionized at the anode. For generating electricity ions releases electrons that flow through the external electrical circuit. When the hydrogen ions pass from the electrolyte to the cathode the electrochemical circuit is formed as they mix with atmospheric oxygen to generate water. As a result, fuel cells are far more effective in turning fuel into electricity, generating no harmful pollutants and wasting little heat. These cells are also better for many other uses like transportation, backup power, and portable energy as they provide consistent results and silently operate. The recent technological developments in the fuel cell market have immensely improved its performance and efficiency, expanding the market.

Download a detailed overview:

https://www.skyquestt.com/sample-request/fuel-cell-market

Extensive and Successful Campaigns by Various Institutions to Augment Demand for EV

Successful campaigns endorsing electric cars, or EVs, are a significant factor propelling the fuel cell industry. Campaigns like these raise awarenesses of the advantages of fuel cell technology in electric vehicles (EVs).Nowadays, as people have become more environmental conscious companies try to focus on benefits like zero emissions and better driving feasibilityduring branding to attract more customers. Such smart marketing strategies are increasing the demand for fuel cells.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/fuel-cell-market

Minimizing Greenhouse Gas with Renewable Sources is Boosting Market

In the last few years, there has been immense pressure on the automobile companies to reduce emissions. This has boosted the growth of the fuel cell market immensely as it relies on renewable sources of energy. This is because governments andindustries are placing greater emphasis on sustainable development. An increase in reliance on energy sources leads to an increase in investment in fuel cell technology, asthe basic function of fuel cells is to generate energy through the ecologically benign conversion of hydrogen or other renewable fuels into electricity. As a result, the market grows rapidly as stakeholders seek alternative energy sources instead of the harmful substance that harmsthe environment. A prototype of Honda’s next-generation hydrogen fuel cellsystem was on show at European Hydrogen Week in Brussels in November 2023, organized by Honda and General Motors.

  • On October 2023, TECO 2030 built hydrogen fuel cells for ships and heavy-duty applications to operate emission-free. These fuel cells can generate clean energy with innovative technologies.
  • In November 2023, Honda along with General Motors launched a prototype of their hydrogen fuel system at the European Hydrogen Week in Brussels.
  • Cochin Shipyard Limited initiated a research project in January 2023 to develop a hydrogen-powered electric vessel utilizing low-temperature proton exchange membrane technology.
  • In December 2023, General Motors and Komatsu announced their intention to form a partnership aimed at developing a hydrogen fuel cell power module for Komatsu’s 930E electric drive mining truck. In Japan, the truck is most use in the construction sector.

 

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/fuel-cell-market

Today, with innovative technologies and rising demand for EVs there are many opportunities for the fuel cell market. New innovative materials and designs are also increasing the efficiency and performance of the cells. In recent times, the transportation sector has become a huge market for fuel cells because of fuel cell electric cars (FCEVs). These cars have better range and faster refilling times compared to BEVs. The fuel cell market will witness significant growth because of the reducing expense of FCEVs and increasing use of hydrogen. Companies in the market also constantly launch new products to maintain a competitive edge in this ever-evolving market.

Related Reports:

Quantum Computing Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/fuel-cell-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fuel Cell Market Forecast to Grow at 27.1% CAGR from 2024 to 2031 | SkyQuest Technology

Medical Device Contract Manufacturing Market worth $149.4 billion in 2029

“The medical device contract manufacturing market is segmented into five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa and GCC countries”
Browse 407 market data Tables and 65 Figures spread through 446 Pages and in-depth TOC on “Medical Device Contract Manufacturing Market by Device Type (IVD, Cardiovascular, Drug Delivery (Autoinjectors, Infusion Device), Diabetes Care, Orthopedic, Ophthalmology, Endoscopy, Surgical), Device Class (I, II, III), Services -Global Forecast to 2029

The report “Medical Device Contract Manufacturing Market by Device Type (IVD, Cardiovascular, Drug Delivery (Autoinjectors, Infusion Device), Diabetes Care, Orthopedic, Ophthalmology, Endoscopy, Surgical), Device Class (I, II, III), Services -Global Forecast to 2029″, is projected to reach USD 149.4 billion in 2029 from USD 78.9 billion in 2023, at a CAGR of 11.4% between 2024 and 2029.

Browse 407 market data Tables and 65 Figures spread through 446 Pages and in-depth TOC on “Medical Device Contract Manufacturing Market by Device Type (IVD, Cardiovascular, Drug Delivery (Autoinjectors, Infusion Device), Diabetes Care, Orthopedic, Ophthalmology, Endoscopy, Surgical), Device Class (I, II, III), Services -Global Forecast to 2029″View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/medical-device-contract-manufacturing-market-170622851.html

The global population is growing older, leading to an increased demand for medical devices used in diagnostics, treatment, and monitoring of age-related conditions also chronic diseases like diabetes, heart disease, and cancer are becoming increasingly prevalent worldwide, necessitating a rise in the demand for medical devices used in their management. which is expected to drive the market growth. However, stringent regulatory compliances for the approval of medical devices is expected to challenge the growth of the market.

“Based on medical device contract manufacturing devices by IVD device type, the IVD consumables segment is expected to grow at the highest CAGR during the forecast period.”

Under IVD device type, IVD consumables is forecasted to grow at the highest CAGR from 2024 to 2029. IVD consumables, the disposable components used in In Vitro Diagnostics (tests conducted outside the living body), offer several advantages that contribute to efficient and accurate medical diagnoses. IVD consumables are designed and manufactured following strict specifications, ensuring consistent performance across various tests and batches. This minimizes the risk of errors due to variations in the testing environment.

“The primary & secondary packing segment is expected to account for the largest share, by packaging & assembly services in the medical device contract manufacturing market.”

By packaging & assembly services in service segment, the medical device contract manufacturing market can be segmented into primary & secondary packing, labelling and others. The advantages of primary and secondary packaging segment by protecting the device from contamination and damage during transport, storage, and handling, is expected to drive the segment growth.

“In 2023, Europe was the region with the second largest market share in the medical device contract manufacturing market“

The medical device contract manufacturing market is segmented into five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa and GCC countries

Europe accounted for the second-largest share of the medical device contract manufacturing market in 2023. The apidly aging population, leading to a higher demand for medical devices used in diagnosing, treating, and monitoring age-related condition is driving the growth of the medical device contract manufacturing market in the European region.

Key players in the medical device contract manufacturing market include Flex Ltd. (Singapore), Jabil Inc. (US), TE Connectivity Ltd. (Switzerland), Sanmina Corporation (US), Nipro Corporation (Japan), Celestica Inc. (Canada), Plexus Corp. (US), Integer Holdings Corporation (US), West Pharmaceutical Services, Inc. (US), Benchmark Electronics Inc. (US), Recipharm AB (Sweden), Gerresheimer AG (Germany), Kimball Electronics Inc. (US), Nortech Systems, Inc. (US), Nemera Development S.A. (France), Viant Medical Holdings, Inc. (US), Tecomet, Inc. (US), SMC Ltd. (US), Phillips-Medisize Corporation (US), Tessy Plastics Corp. (US), Carclo Plc (UK), Nolato GW, Inc. (US), MeHow (China), Tekni-Plex (US), and Peter’s Technology (China).

Don’t miss out on business opportunities in Medical Device Contract Manufacturing Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.prnewswire.com/news-releases/medical-device-contract-manufacturing-market-worth-149-4-billion–marketsandmarkets-302094127.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Medical Device Contract Manufacturing Market worth $149.4 billion in 2029

Wastewater Reverse Osmosis Membrane Market Size Analysis, Growth, Opportunities, Top Manufacturers, Key Segmentation, Regional Analysis, and Forecast to 2028

“Browse 161 market data Tables and 47 Figures spread through 196 Pages and in-depth TOC on “Wastewater Reverse Osmosis Membrane Market””
The Wastewater Reverse Osmosis Membrane Market is growing due to rising demand for efficient water treatment solutions. Key drivers include industrial wastewater management and desalination projects, with significant growth in Asia-Pacific and North America.

The wastewater reverse osmosis membrane market is projected to reach USD 1.6 billion by 2028, at a CAGR of 9.9% from USD 0.9 billion in 2023. The growth of the global wastewater reverse osmosis membrane market is driven by increasing demand for wastewater treatment. The declining freshwater resource and the government regulations for the treatment of industrial and municipal wastewater are also driving the wastewater reverse osmosis membrane market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30789810 

Wastewater Reverse Osmosis Membrane Companies

The key global players in the wastewater reverse osmosis membrane market are DuPont (US), Toray Industries, Inc. (Japan), Veolia (France), Alfa Laval (Sweden), LG Chem (South Korea), Hydranautics (US), KOCH Separation Solutions (US), Mann + Hummel Water & Fluid Solutions GmbH (Germany), Memorandum (Russia), and Toyobo Co. Ltd (Japan) among others. These companies are strong in their home regions and explore geographic diversification alternatives to grow their businesses. They focus on increasing their market shares through new product launches and other expansions.

Toray Industries, Inc

Toray Industries, Inc. is a leading integrated chemical industry group headquartered in Tokyo, Japan. The company operates in various business segments, namely, fibers & textile, performance chemicals, carbon fiber composite materials, environment & engineering, life science, and other services. The company provides water treatment membranes, water treatment systems, and water purifiers under its environment & engineering segment and provides RO membranes through a separate division called Toray Membrane. This division provides a wide product portfolio, which includes a full range of cross-linked polyamide composite membranes.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=30789810 

In July 2022, Toray Industries, Inc. significantly enhanced its wastewater treatment facility in China, located in Baoding, Hebei Province. This state-of-the-art plant, among the largest in the country, specializes in producing hollow fiber membrane modules. With a daily treatment capacity of 315,000 cubic meters, the advanced facility has enabled the company to deliver cutting-edge technology and superior water treatment membrane products.

LG Chem

LG Chem is one of the largest chemical companies in South Korea. The group is engaged in petrochemicals, energy solutions, advanced material business, and life science business. The company offers RO membranes under its advanced material business. The company covers broad spectrum of applications, ranging from industrial water treatment to residential water purification systems. The company’s RO membranes are designed to deliver high-performance filtration, ensuring the removal of impurities, contaminants, and salts from water, thereby producing clean and potable water. LG Chem has NanoH2O RO membrane product line, which has a wide range of products for desalination, industrial wastewater treatment, water-reuse, potable water, and others. This product range caters to the needs of various customers.

In July 2023, The company has invested USD 100 million in Cheongju RO membrane plant. This expansion will double the water treatment business of company within 5 years and will help in strengthen their position as global leader in ro membrane.

Request Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=30789810 

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/wastewater-reverse-osmosis-membrane-market-30789810.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Wastewater Reverse Osmosis Membrane Market Size Analysis, Growth, Opportunities, Top Manufacturers, Key Segmentation, Regional Analysis, and Forecast to 2028

Genetic Testing Market to Stand Tall with a Striking 22% CAGR through 2031

“Skyquest Technology”
Genetic Testing Market Size, Share, Growth Analysis, By Product(Consumables, Equipment, Software and Services), By Technology(Next-generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Chemiluminescence Immunoassay), By Testing Type(Predictive Testing and Presymptomatic Testing, Carrier Testing, Prenatal and Newborn Testing, Preimplantation Testing), By Region – Industry Forecast 2024-2031

Genetic Testing Market size was valued at USD 6.08 billion in 2022 and is poised to grow from USD 7.42 billion in 2023 to USD 36.40 billion by 2031, growing at a CAGR of 22% in the forecast period (2024-2031). 

The Global Genetic Testing Market holds potential advantages due to improvements in genomics and genetics. This is ultimately transforming the medical practice, impacting substantial growth of genetic testing in the healthcare sector. As the accessibility to genetic testing is increasing, the improvements in sequencing technologies along with reducing costs are driving the market.

Genetic testing plays a crucial part in identifying the risk of developing specific illnesses, screening, and at times medical treatment as well. Different kinds of genetic testing are performed for diverse reasons. In diagnostic testing, if a patient has symptoms of an illness that could be due to genetic changes or mutated genes, genetic testing can help show that he/she has the doubted illness. Pre-symptomatic & predictive testing, if the patient’s family history has a genetic condition, getting this testing might tell the patient if he/she might get it in the future. In carrier testing, if the patient’s family has a history of cystic fibrosis or anemia, it is better to have the testing done before planning for a child. In Pharmacogenetics, if the patient has a certain disease or condition, this genetic testing will help know which dosage or medicines will be highly beneficial. For prenatal testing, a pregnant lady can early detect signs of irregularities in the baby’s genes.

Download a detailed overview:

https://www.skyquestt.com/sample-request/genetic-testing-market

Shift Towards Genotyping and Genetic Testing to Enhance Personalized Treatments in the Market

Currently, innovations in genetics study have remarkably contributed to and improved the emerging domain of personalized treatment. Moreover, it has majorly advanced the risk factor examination of diseases and early detection of disease, informed lifestyle changes to lessen risks backed the reproductive health and genetic counseling information, and also guided the existing research efforts and clinical trials. Personalized medicine emphasizes patient-centered care with improvements in artificial intelligence, genetic pathology registries, and bioinformatics, thereby majorly enhancing health. With more and more healthcare professionals accepting that medicines are not multipurpose or not adaptable for all, they are inclined towards genetic testing and genotyping to better understand the health of the patient and which treatments are suitable for them. In clinical practice, experts can compare the genetic information of patients to the datasets of variants to know if the patient is susceptible to any illness. Genetic testing can also offer insights into pharmacogenetics. This will allow doctors to determine the ideal treatment depending on the patient’s genetic differences.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/genetic-testing-market

  • In September 2023, Deep Genomics introduced the highly improved Artificial Intelligence Foundation Model for RNA (Ribonucleic Acid) Candidate Therapeutics and Disease Mechanisms. As mentioned in the manuscript, the BigRNA correctly projects the tissue-based regulatory mechanisms of the RNA expression and also the binding sites of microRNAs and proteins.
  • Agena Bioscience, a provider of genetic testing solutions announced an association with Manchester University to expand access and awareness to pharmacogenomics educational resources in November 2021. Manchester University institution offers innovative PGx educational programs within laboratory and healthcare sciences.
  • In May 2022, Myriad Genetics improved its technique of genetic testing to offer women the information they want to remain healthy. The company has been in genetic testing for women with breast cancer for the past 30 years. Lately, it developed an extensive platform that incorporates extra epidemiological risk factors and ancestry genetic markers into conventional testing methods. The goal is to offer patients more sense of the danger of the development of breast cancer.

 

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/genetic-testing-market

Direct-to-consumer genetic tests are gaining popularity and governments are actively planning to gather and use genetic data in research and clinical settings. Hence, the quantity of genetic data at disposal will speedily increase. Genetic testing will become more and more useful in the years to come and will play a crucial role in several aspects of healthcare and medicine.

Related Reports:

Robotics Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/genetic-testing-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Genetic Testing Market to Stand Tall with a Striking 22% CAGR through 2031